Efficacy of captopril in low-renin congestive heart failure: Importance of sustained reactive hyperreninemia in distinguishing responders from nonresponders

Milton Packer, Norma Medina, Madeline Yushak

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

To determine the efficacy of converting-enzyme inhibition in patients with low-renin congestive heart failure (CHF), the long-term hemodynamic and clinical responses to captopril were evaluated in 26 consecutive patients with severe, chronic CHF whose pretreatment plasma renin activity (PRA) was <2 ng/ml/hour. After 2 to 8 weeks of continuous treatment with captopril, 14 patients (54%) showed long-term hemodynamic benefits, of whom 13 (50%) improved clinically by at least 1 New York Heart Association functional class. To distinguish responders from nonresponders, patients were grouped based on the presence or absence of sustained reactive hyperreninemia (PRA during chronic therapy >4 ng/ml/hour). After 2 to 8 weeks of therapy with captopril, 14 patients had sustained reactive hyperreninemia. Their cardiac index increased by 0.33 liters/min/m2 (p <0.01), left ventricular filling pressure decreased by 12.6 mm Hg (p <0.001), mean right atrial pressure decreased by 4.9 mm Hg (p <0.001) and systemic vascular resistance decreased by 529 dyne s cm-5 (p <0.001). Twelve of these 14 patients patients improved clinically. Twelve other patients had no reactive increase in PRA, and these patients showed no significant improvement in any hemodynamic variable after 2 to 8 weeks of treatment with captopril; only 1 of the 12 patients improved clinically (p <0.001 between groups). The 2 groups were otherwise similar with regard to pretreatment demographic, hemodynamic and hormonal variables. Thus, many patients with severe, chronic CHF associated with a low PRA improve during therapy with captopril, and these patients can be distinguished from nonresponders by the occurrence of reactive hyperreninemia during long-term treatment.

Original languageEnglish (US)
Pages (from-to)771-777
Number of pages7
JournalThe American Journal of Cardiology
Volume54
Issue number7
DOIs
StatePublished - Oct 1 1984

Fingerprint

Captopril
Renin
Heart Failure
Hemodynamics
Atrial Pressure
Ventricular Pressure
Therapeutics
Vascular Resistance
Demography

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Efficacy of captopril in low-renin congestive heart failure : Importance of sustained reactive hyperreninemia in distinguishing responders from nonresponders. / Packer, Milton; Medina, Norma; Yushak, Madeline.

In: The American Journal of Cardiology, Vol. 54, No. 7, 01.10.1984, p. 771-777.

Research output: Contribution to journalArticle

@article{0d98102bc74e4719b242aa4128c3de71,
title = "Efficacy of captopril in low-renin congestive heart failure: Importance of sustained reactive hyperreninemia in distinguishing responders from nonresponders",
abstract = "To determine the efficacy of converting-enzyme inhibition in patients with low-renin congestive heart failure (CHF), the long-term hemodynamic and clinical responses to captopril were evaluated in 26 consecutive patients with severe, chronic CHF whose pretreatment plasma renin activity (PRA) was <2 ng/ml/hour. After 2 to 8 weeks of continuous treatment with captopril, 14 patients (54{\%}) showed long-term hemodynamic benefits, of whom 13 (50{\%}) improved clinically by at least 1 New York Heart Association functional class. To distinguish responders from nonresponders, patients were grouped based on the presence or absence of sustained reactive hyperreninemia (PRA during chronic therapy >4 ng/ml/hour). After 2 to 8 weeks of therapy with captopril, 14 patients had sustained reactive hyperreninemia. Their cardiac index increased by 0.33 liters/min/m2 (p <0.01), left ventricular filling pressure decreased by 12.6 mm Hg (p <0.001), mean right atrial pressure decreased by 4.9 mm Hg (p <0.001) and systemic vascular resistance decreased by 529 dyne s cm-5 (p <0.001). Twelve of these 14 patients patients improved clinically. Twelve other patients had no reactive increase in PRA, and these patients showed no significant improvement in any hemodynamic variable after 2 to 8 weeks of treatment with captopril; only 1 of the 12 patients improved clinically (p <0.001 between groups). The 2 groups were otherwise similar with regard to pretreatment demographic, hemodynamic and hormonal variables. Thus, many patients with severe, chronic CHF associated with a low PRA improve during therapy with captopril, and these patients can be distinguished from nonresponders by the occurrence of reactive hyperreninemia during long-term treatment.",
author = "Milton Packer and Norma Medina and Madeline Yushak",
year = "1984",
month = "10",
day = "1",
doi = "10.1016/S0002-9149(84)80206-4",
language = "English (US)",
volume = "54",
pages = "771--777",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Efficacy of captopril in low-renin congestive heart failure

T2 - Importance of sustained reactive hyperreninemia in distinguishing responders from nonresponders

AU - Packer, Milton

AU - Medina, Norma

AU - Yushak, Madeline

PY - 1984/10/1

Y1 - 1984/10/1

N2 - To determine the efficacy of converting-enzyme inhibition in patients with low-renin congestive heart failure (CHF), the long-term hemodynamic and clinical responses to captopril were evaluated in 26 consecutive patients with severe, chronic CHF whose pretreatment plasma renin activity (PRA) was <2 ng/ml/hour. After 2 to 8 weeks of continuous treatment with captopril, 14 patients (54%) showed long-term hemodynamic benefits, of whom 13 (50%) improved clinically by at least 1 New York Heart Association functional class. To distinguish responders from nonresponders, patients were grouped based on the presence or absence of sustained reactive hyperreninemia (PRA during chronic therapy >4 ng/ml/hour). After 2 to 8 weeks of therapy with captopril, 14 patients had sustained reactive hyperreninemia. Their cardiac index increased by 0.33 liters/min/m2 (p <0.01), left ventricular filling pressure decreased by 12.6 mm Hg (p <0.001), mean right atrial pressure decreased by 4.9 mm Hg (p <0.001) and systemic vascular resistance decreased by 529 dyne s cm-5 (p <0.001). Twelve of these 14 patients patients improved clinically. Twelve other patients had no reactive increase in PRA, and these patients showed no significant improvement in any hemodynamic variable after 2 to 8 weeks of treatment with captopril; only 1 of the 12 patients improved clinically (p <0.001 between groups). The 2 groups were otherwise similar with regard to pretreatment demographic, hemodynamic and hormonal variables. Thus, many patients with severe, chronic CHF associated with a low PRA improve during therapy with captopril, and these patients can be distinguished from nonresponders by the occurrence of reactive hyperreninemia during long-term treatment.

AB - To determine the efficacy of converting-enzyme inhibition in patients with low-renin congestive heart failure (CHF), the long-term hemodynamic and clinical responses to captopril were evaluated in 26 consecutive patients with severe, chronic CHF whose pretreatment plasma renin activity (PRA) was <2 ng/ml/hour. After 2 to 8 weeks of continuous treatment with captopril, 14 patients (54%) showed long-term hemodynamic benefits, of whom 13 (50%) improved clinically by at least 1 New York Heart Association functional class. To distinguish responders from nonresponders, patients were grouped based on the presence or absence of sustained reactive hyperreninemia (PRA during chronic therapy >4 ng/ml/hour). After 2 to 8 weeks of therapy with captopril, 14 patients had sustained reactive hyperreninemia. Their cardiac index increased by 0.33 liters/min/m2 (p <0.01), left ventricular filling pressure decreased by 12.6 mm Hg (p <0.001), mean right atrial pressure decreased by 4.9 mm Hg (p <0.001) and systemic vascular resistance decreased by 529 dyne s cm-5 (p <0.001). Twelve of these 14 patients patients improved clinically. Twelve other patients had no reactive increase in PRA, and these patients showed no significant improvement in any hemodynamic variable after 2 to 8 weeks of treatment with captopril; only 1 of the 12 patients improved clinically (p <0.001 between groups). The 2 groups were otherwise similar with regard to pretreatment demographic, hemodynamic and hormonal variables. Thus, many patients with severe, chronic CHF associated with a low PRA improve during therapy with captopril, and these patients can be distinguished from nonresponders by the occurrence of reactive hyperreninemia during long-term treatment.

UR - http://www.scopus.com/inward/record.url?scp=0021190001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021190001&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(84)80206-4

DO - 10.1016/S0002-9149(84)80206-4

M3 - Article

C2 - 6091434

AN - SCOPUS:0021190001

VL - 54

SP - 771

EP - 777

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -